0001638599-18-001327.txt : 20181206 0001638599-18-001327.hdr.sgml : 20181206 20181206060127 ACCESSION NUMBER: 0001638599-18-001327 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181204 FILED AS OF DATE: 20181206 DATE AS OF CHANGE: 20181206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Mahesh V. CENTRAL INDEX KEY: 0001579872 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 181218610 MAIL ADDRESS: STREET 1: C/O LIPOCINE, INC. STREET 2: 675 ARAPEEN DRIVE, STE. 202 CITY: SALT LAKE CITY STATE: UT ZIP: 84108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 4 1 doc4_5817.xml PRIMARY DOCUMENT X0306 4 2018-12-04 0 0001535955 Lipocine Inc. LPCN 0001579872 Patel Mahesh V. 675 ARAPEEN DRIVE SUITE 202 SALT LAKE CITY UT 84010 1 1 0 0 President and CEO Restricted stock unit 0 2018-12-04 4 A 0 290000 0 A 2019-12-04 2028-12-04 Common Stock 290000 290000 D Stock Option (Right to Buy) 1.46 2018-12-04 4 A 0 150000 1.46 A 2019-12-04 2028-12-04 Common Stock 150000 150000 D Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 4, 2019, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. /s/Mahesh Patel 2018-12-05